BENGALURU (Reuters) - India's Amrutanjan Health Care reported a 35.7% slide in second-quarter profit on Friday, hurt by a rise in expenses and weakening sales of its wellness products as the pandemic's effects wane.

Demand for healthcare products was tapering off the highs of the past two years, as the number of infections comes off peaks, the Chennai-based company said last quarter.

Revenue from the company's over-the-counter (OTC) business, which includes pain relief products such as the Amrutanjan pain balm and Relief Cold Rub, slipped 0.2% to 1 billion rupees, accounting for 94% of total revenue.

Total revenue from operations rose 0.3% to 1.11 billion rupees, said the company, which also sells beverages such as the Fruitnik drinks.

Amrutanjan's cost of raw materials and components consumed fell 6.2% in the quarter. However, total expenses increased 9.1%, ultimately weighing on margins.

Profit before tax at the mainstay OTC segment fell 27% from a year ago, while the beverages segment, already under pressure, swung to a loss in the latest quarter from a year-ago profit.

The company's stock closed up 1.7% on Friday, cutting its losses for the year to about 20%. ($1 = 82.2830 Indian rupees)

(Reporting by Yagnoseni Das in Bengaluru; Editing by Savio D'Souza)